Immunomodulation of NF-κB activation has been proven effective in SARS-CoV-infected cells or mice.146 Thus, recent reviews have proposed that the NF-κB pathway represents a potential therapeutic target for critical COVID-19 illness.336–338. This evidence concerns the gene NFKB1 and COVID-19.